Literature DB >> 26209654

Local axonal protection by WldS as revealed by conditional regulation of protein stability.

Jack T Wang1, Zachary A Medress2, Mauricio E Vargas3, Ben A Barres1.   

Abstract

The expression of the mutant Wallerian degeneration slow (WldS) protein significantly delays axonal degeneration from various nerve injuries and in multiple species; however, the mechanism for its axonal protective property remains unclear. Although WldS is localized predominantly in the nucleus, it also is present in a smaller axonal pool, leading to conflicting models to account for the WldS fraction necessary for axonal protection. To identify where WldS activity is required to delay axonal degeneration, we adopted a method to alter the temporal expression of WldS protein in neurons by chemically regulating its protein stability. We demonstrate that continuous WldS activity in the axonal compartment is both necessary and sufficient to delay axonal degeneration. Furthermore, by specifically increasing axonal WldS expression postaxotomy, we reveal a critical period of 4-5 h postinjury during which the course of Wallerian axonal degeneration can be halted. Finally, we show that NAD(+), the metabolite of WldS/nicotinamide mononucleotide adenylyltransferase enzymatic activity, is sufficient and specific to confer WldS-like axon protection and is a likely molecular mediator of WldS axon protection. The results delineate a therapeutic window in which the course of Wallerian degeneration can be delayed even after injures have occurred and help narrow the molecular targets of WldS activity to events within the axonal compartment.

Entities:  

Keywords:  NAD+; Wallerian degeneration; WldS; axon degeneration; axotomy

Mesh:

Substances:

Year:  2015        PMID: 26209654      PMCID: PMC4547231          DOI: 10.1073/pnas.1508337112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo.

Authors:  Elisabetta Babetto; Bogdan Beirowski; Lucie Janeckova; Rosalind Brown; Jonathan Gilley; Derek Thomson; Richard R Ribchester; Michael P Coleman
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

2.  Axonal degeneration is blocked by nicotinamide mononucleotide adenylyltransferase (Nmnat) protein transduction into transected axons.

Authors:  Yo Sasaki; Jeffrey Milbrandt
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

3.  Chemical genetic-mediated spatial regulation of protein expression in neurons reveals an axonal function for wld(s).

Authors:  Michael S Cohen; Ananda K Ghosh; Hyung Joon Kim; Noo Li Jeon; Samie R Jaffrey
Journal:  Chem Biol       Date:  2012-02-24

4.  Neurotrophins are key mediators of the myelination program in the peripheral nervous system.

Authors:  J R Chan; J M Cosgaya; Y J Wu; E M Shooter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene.

Authors:  T G Mack; M Reiner; B Beirowski; W Mi; M Emanuelli; D Wagner; D Thomson; T Gillingwater; F Court; L Conforti; F S Fernando; A Tarlton; C Andressen; K Addicks; G Magni; R R Ribchester; V H Perry; M P Coleman
Journal:  Nat Neurosci       Date:  2001-12       Impact factor: 24.884

6.  Axonal Localization of transgene mRNA in mature PNS and CNS neurons.

Authors:  Dianna E Willis; Mei Xu; Christopher J Donnelly; Chhavy Tep; Marvin Kendall; Marina Erenstheyn; Arthur W English; N Carolyn Schanen; Catherine B Kirn-Safran; Sung Ok Yoon; Gary J Bassell; Jeffery L Twiss
Journal:  J Neurosci       Date:  2011-10-12       Impact factor: 6.167

7.  Axonally synthesized β-actin and GAP-43 proteins support distinct modes of axonal growth.

Authors:  Christopher J Donnelly; Michael Park; Mirela Spillane; Soonmoon Yoo; Almudena Pacheco; Cynthia Gomes; Deepika Vuppalanchi; Marguerite McDonald; Hak Hee Kim; Hak Kee Kim; Tanuja T Merianda; Gianluca Gallo; Jeffery L Twiss
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

8.  Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria.

Authors:  Brandon M Kitay; Ryan McCormack; Yunfang Wang; Pantelis Tsoulfas; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2013-01-11       Impact factor: 6.150

9.  Purification and culture of retinal ganglion cells from rodents.

Authors:  Alissa Winzeler; Jack T Wang
Journal:  Cold Spring Harb Protoc       Date:  2013-07-01

10.  A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration.

Authors:  M Di Stefano; I Nascimento-Ferreira; G Orsomando; V Mori; J Gilley; R Brown; L Janeckova; M E Vargas; L A Worrell; A Loreto; J Tickle; J Patrick; J R M Webster; M Marangoni; F M Carpi; S Pucciarelli; F Rossi; W Meng; A Sagasti; R R Ribchester; G Magni; M P Coleman; L Conforti
Journal:  Cell Death Differ       Date:  2014-10-17       Impact factor: 15.828

View more
  19 in total

1.  QnAs with Ben Barres.

Authors:  Ben Barres; Prashant Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-03       Impact factor: 11.205

Review 2.  Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.

Authors:  Josiah Gerdts; Daniel W Summers; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Neuron       Date:  2016-02-03       Impact factor: 17.173

Review 3.  Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.

Authors:  Heather S Loring; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2019-11-21       Impact factor: 8.116

4.  Identification of the first noncompetitive SARM1 inhibitors.

Authors:  Heather S Loring; Sangram S Parelkar; Santanu Mondal; Paul R Thompson
Journal:  Bioorg Med Chem       Date:  2020-07-17       Impact factor: 3.641

5.  Role of SARM1 and DR6 in retinal ganglion cell axonal and somal degeneration following axonal injury.

Authors:  Kimberly A Fernandes; Katherine L Mitchell; Amit Patel; Olivia J Marola; Peter Shrager; Donald J Zack; Richard T Libby; Derek S Welsbie
Journal:  Exp Eye Res       Date:  2018-03-08       Impact factor: 3.467

Review 6.  Axon degeneration: context defines distinct pathways.

Authors:  Matthew J Geden; Mohanish Deshmukh
Journal:  Curr Opin Neurobiol       Date:  2016-05-16       Impact factor: 6.627

7.  Sarm1 loss reduces axonal damage and improves cognitive outcome after repetitive mild closed head injury.

Authors:  Mark E Maynard; John B Redell; Jing Zhao; Kimberly N Hood; Sydney M Vita; Nobuhide Kobori; Pramod K Dash
Journal:  Exp Neurol       Date:  2020-01-18       Impact factor: 5.330

Review 8.  A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity.

Authors:  Eleanor L Hopkins; Weixi Gu; Bostjan Kobe; Michael P Coleman
Journal:  Front Mol Biosci       Date:  2021-07-08

Review 9.  Programmed axon degeneration: from mouse to mechanism to medicine.

Authors:  Michael P Coleman; Ahmet Höke
Journal:  Nat Rev Neurosci       Date:  2020-03-09       Impact factor: 34.870

10.  A phase transition enhances the catalytic activity of SARM1, an NAD+ glycohydrolase involved in neurodegeneration.

Authors:  Heather S Loring; Victoria L Czech; Janneke D Icso; Lauren O'Connor; Sangram S Parelkar; Alexandra B Byrne; Paul R Thompson
Journal:  Elife       Date:  2021-06-29       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.